Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · as published 2026-06-30 View official record Methodology

Covered recipient · General Payments record

MICHAEL G SHLIPAK

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1073541132
CMS profile
1048600
Location
SAN FRANCISCO, CA

General Payments · PY2020–2025

$36,500.68

  • Reported across 33 records
  • CMS publication 2026-06-30

Latest program year · PY2025

$15,413.53

13 records · 0 disputed

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How these totals are calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

PY2025 · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $14,155.00 4
Travel and Lodging $951.64 3
Food and Beverage $306.89 6

By paying entity

PY2025 · sorted by reported total

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2020 $2,750.00 1
PY2021 $2,227.50 2
PY2022 $14,547.23 11
PY2023 $1,562.42 6
PY2025 $15,413.53 13

Payment records · PY2025 (13)

Sorted by paying entity, then date · as published by CMS

Program year 2025 2020202120222023 Record-level detail is published for PY2025; earlier years are summarised in “By program year”.
Paying entity Amount Date Nature of payment Dispute status Published Record ID Source
Bayer Healthcare Pharmaceuticals Inc. $778.50 05/27/2025 Consulting Fee Undisputed 06/30/2026 1225796804 CMS
Bayer Healthcare Pharmaceuticals Inc. $1,816.50 06/24/2025 Consulting Fee Undisputed 06/30/2026 1225796808 CMS
Boehringer Ingelheim International GmbH $2,550.00 09/22/2025 Consulting Fee Undisputed 06/30/2026 1215868581 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $569.96 05/22/2025 Travel and Lodging Undisputed 06/30/2026 1223040867 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $47.70 06/18/2025 Food and Beverage Undisputed 06/30/2026 1223040855 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $47.70 06/18/2025 Food and Beverage Undisputed 06/30/2026 1223040857 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $38.16 06/18/2025 Food and Beverage Undisputed 06/30/2026 1223040859 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $38.16 06/18/2025 Food and Beverage Undisputed 06/30/2026 1223040861 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $100.17 06/18/2025 Food and Beverage Undisputed 06/30/2026 1223040863 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $241.68 06/18/2025 Travel and Lodging Undisputed 06/30/2026 1223040865 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $140.00 08/12/2025 Travel and Lodging Undisputed 06/30/2026 1223040869 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $9,010.00 08/12/2025 Consulting Fee Undisputed 06/30/2026 1223040871 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $35.00 08/12/2025 Food and Beverage Undisputed 06/30/2026 1223040873 CMS

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2020, 2021, 2022, 2023, 2025
Source files
Dataset page · Bulk file · PY2020 , PY2021 , PY2022 , PY2023 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.